Alluvi, initially dubbed LY3414901, represents a exciting advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist shows remarkable efficacy in early medical data, with considerable slimming obs